Background: Perioperative epirubicin, cisplatin and fluorouracil (ECF) chemotherapy improves survival in operable oesophago-gastric cancer [Adjuvant Gastric Cancer Infusional Chemotherapy (MAGIC) trial HR 0.75 (0.6-0.93)]. HER2 amplification is reported to predict enhanced benefit from anthracyclines in breast cancer. We sought to define whether HER2 predicts benefit from ECF in oesophago-gastric cancer.
tolerated, but can result in significant morbidity and even death. Reliable biomarkers are therefore needed to improve outcomes by allowing selection of those who will benefit from CSC, S or investigation of new therapies.
The anti-HER2 monoclonal antibody trastuzumab combined with cisplatin-fluoropyrimidine chemotherapy is a standard treatment of HER2-positive advanced oesophago-gastric adenocarcinoma, mandating routine testing of HER2 in this setting [3] . Targeting HER2 in early-stage disease is now being investigated, including evaluation of the small molecule inhibitor of EGFR and HER2, lapatinib, within the MRC's ongoing ST03 study.
In breast cancer, HER2 amplification is a potential predictive biomarker of epirubicin sensitivity [4] [5] [6] [7] , probably due to coamplification with the Topoisomerase IIα gene (TOP2A), located close to HER2 on chromosome 17q21 [8, 9] . TOP2A cleaves and re-ligates double-stranded DNA, is a key enzyme in DNA replication and repair, and the molecular target of anthracyclines, which stabilise the cleavable complexes formed by topoisomerases; causing DNA breaks and cell death [10] . The role of HER2 and TOP2A gene status as predictive markers for response to anthracycline-based chemotherapy has proven controversial.
In gastric cancer, the significance of HER2 as a prognostic biomarker remains unclear, with conflicting reports [11] [12] [13] [14] , possibly reflecting variation in HER2 testing and scoring before the introduction of a standardised scoring system [15, 16] . We therefore sought to determine whether HER2 status would constitute a predictive marker for response to ECF, and/or a prognostic marker, in localised oesophago-gastric cancer.
materials and methods

study population and design
All patients gave written informed consent to participate in the MAGIC trial (results previously published) [1] . In brief, 503 patients with potentially operable oesophago-gastric adenocarcinoma were randomised to surgery (n = 253) or peri-operative ECF chemotherapy (n = 250). The TransMAGIC study was subsequently designed to determine whether tumour biomarkers could predict benefit from peri-operative ECF. Additional consent was not sought from surviving patients; therefore samples were studied anonymised; identifiable by histology number, study number and initials only. This amendment to the MAGIC study was approved by the South East Research Ethics Committee (Ref 11/LO/0566).
Paraffin-embedded samples from the diagnostic biopsy and resection (where applicable) were requested for all 503 patients randomised from 55 centres predominantly in the UK. Approval was obtained from institutional review boards according to local and national requirements.
All tumours were reviewed, and classified according to World Health Organisation classification [17] by one specialist gastrointestinal cancers pathologist (AW) who was blinded to treatment allocation and outcome.
histological review and tissue microarray construction
Forty-nine of 55 centres agreed to participate in the study and paraffinembedded blocks from the diagnostic biopsy, resection or both were received for 415 of 503 patients. Of these, 404 had sufficient material for tissue microarray (TMA) construction. Two cases found to be neuroendocrine tumours on central review (both allocated to S) were excluded. Of 402 remaining patients (79.9%), pre-treatment biopsies were included for 244 of 503 patients (48.5%), and resections or post-treatment biopsies for 337 patients (67.0%). Paired samples were available for 179 of 503 patients (35.6%); shown by treatment arm in Figure 1 .
TMAs were constructed from representative blocks from the trial specimens, and were composed of replicate 1-mm cores from each case and controls (i.e. samples of non-neoplastic kidney, liver, placenta, small bowel or normal stomach) as previously described [18] . For biopsy specimens, 0.5-mm-diameter cores were used due to limited available tissue.
immunohistochemistry and brightfield dual in situ hybridisation
Immunohistochemical (IHC) testing was carried out on all available resection specimens and biopsies with confirmed adenocarcinoma. HER2 expression was detected using the PATHWAY anti-HER2/neu (4B5) antibody on an automated immuno-stainer (Benchmark® XT Ventana, Medical Systems Inc., Tucson, AZ), according to manufacturer's instructions.
All resections were subjected to brightfield dual in situ hybridisation (BDISH) testing. Owing to limited tissue available from pre-treatment biopsies, BDISH testing was limited to biopsies without paired resections, IHC2+ biopsies and biopsies with paired BDISH positive resections (to confirm the result).
The BenchMark® XT automated slide processing system (Ventana Medical Systems, Inc., Tucson, Arizona) was used for the BDISH assay for HER2 and centromere probe on chromosome 17 (CEP 17) DNA targets, which was previously validated against FISH [19] .
Full-face tissue sections (where available) were employed for IHC and/or BDISH using adjusted protocols in cases where results were unavailable due to technical failures (e.g. differences in fixation of the paraffinembedded samples).
microscopic analysis and scoring
One pathologist (AW) examined representative TMA sections subjected to IHC with antibodies against HER2 according to published guidelines [15, 16] . In brief, for IHC, all samples evaluated on the TMAs were scored as recommended for biopsies; requiring a minimum of five cells showing strong reactivity to score IHC3+. HER2 negative was defined as 0-1+, 2+ was graded as equivocal and HER2 positive as 3+. Technical failures were repeated on 3-µm full sections, which for resection specimens were then scored as recommended for resections.
For BDISH, 20 cohesive cells showing highest gene count were counted initially. A ratio of <1.8 was considered negative and >2.2 was positive. For ratios 1.8-2.2, a further 20 cells were counted, and the ratio re-calculated for 40 cells. Samples with a HER2:CEP17 ratio ≥2.0 in 40 cells were then considered positive.
definitions of HER2 positive
For biopsies, HER2 positive was defined by IHC3+ or IHC2+ and BDISH positive (EMEA definition for approval of trastuzumab [20] ). For [21] ), as all samples had been subjected to both IHC and BDISH.
statistical considerations
Sample size was dictated by availability of samples; a priori power calculations indicated that with ∼160 deaths and a marker prevalence of ∼10%, power to detect an interaction effect (ratio of HRs) of 0.25 (0.5) was ∼80% (∼70%).
Analyses of the biopsy and resection samples were carried out separately as the resection rate and, therefore, availability of resection specimens was potentially affected by the allocated treatment arm. Baseline characteristics and survival of relevant patients with and without specimens were compared to assess the representativeness of the sample populations. For subjects with pre-treatment biopsy samples, the comparative population comprises those without biopsy samples, and survival time is calculated from randomisation to date of death from any cause, or last follow-up. For patients with resection specimens the relevant comparative population is all resected patients with no available surgical sample, and survival time is dated from surgery. Oesophageal or OGJ primary tumour [22] [23] [24] [25] , wellmoderated degree of differentiation [24] [25] [26] and intestinal histological subtype [22, 27] have been previously associated with HER2 overexpression; these associations were assessed using Fisher's exact test.
The prognostic value of HER2 status was assessed in each treatment arm separately using Kaplan-Meier survival curves compared with the log-rank test; the treatment groups were combined if a test of heterogeneity of the HER2 hazard ratios (HRs) showed no evidence of differential prognostic effect (heterogeneity P > 0.1). Adjusted multivariable Cox proportional hazards regression models were used to assess the independent prognostic value of HER2 status. All variables that we allow for an effect of, on the prognostic value of HER2 status, were forced into the model along with HER2 status and the prognostic value of HER2 status assessed again. Formal evaluation of HER2 status as a predictor of benefit from ECF chemotherapy could only be undertaken using pre-treatment biopsy specimen results. Here, the treatment HRs in HER2-negative and -positive patients were calculated and tested for heterogeneity, where a P < 0.1 was taken as evidence of potential predictive value.
Cohen's κ coefficient was used to measure concordance between HER2 expression for biopsy and resection specimens, and IHC and BDISH results [28] .
This study is compliant with REMARK guidelines (Table 1 ) [29] .
results
patients' characteristics
Baseline characteristics and survival for the tumour analysis patients and comparable populations without samples are [15, 16] . Standard controls used with each BDISH and IHC run, using BDISH-positive and -negative controls and IHC tissue known to be 1+, 2+ and 3+, respectively. Study design Retrospective analysis of paraffin-embedded material from patients treated within a prospective randomised study. Clinical end-point of overall survival used Sample size determined by the availability of tissue from the 503 randomised patients; with the observed number of deaths power to detect interaction effects (ratio of treatment HRs) was ∼80% for 0.5 and ∼70% for 0.5 Statistical methods
Biopsies and resection samples assessed separately. Associations with site of primary tumour, histological subtype and differentiation assessed using Fisher's exact test Predictive value of HER2 status at biopsy assessed using tests of heterogeneity of the subgroup treatment HRs, displayed in forest plots Prognostic value of HER2 status assessed in each treatment arm separately using Kaplan-Meier survival curves compared with the log-rank test Multivariate analysis using Cox's proportional hazards regression model to assess the independent prognostic value of HER2 status Cohen's κ coefficient used to measure concordance between HER2 expression for biopsy and resection specimens, and IHC and BDISH Results Data Flow of patients detailed in Figure 1 ; baseline characteristics in Table 2 and in supplementary Figure S1 , available at Annals of Oncology online, respectively, and are broadly similar.
HER2 and correlation with clinicopathological and prognostic factors
HER2 results were available on 217 of 244 biopsies and 15 of 217 (7%, 95% CI 4% to 11%) were positive. Of the resection specimens, 34 of 332 were IHC3+ or IHC2+/BDISH+ positive. A further 13 of 332 exhibited HER2 amplification (BDISH ≥ 2) but not protein over-expression (IHC0-1+) ( Table 3) . Significantly more moderately differentiated (P = 0.002) and intestinal cancers (P = 0.034) were HER2 positive (supplementary Tables S1a and S1b, available at Annals of Oncology online).
concordance of expression and amplification of HER2 (resection specimens only)
Concordance between HER2 positive by IHC and BDISH was high; 26 of 27 IHC3+ resection specimens were also BDISH positive (96%). By contrast, 11 of 264 (4.2%) IHC0 and 2 of 22 (9%) IHC 1+resections were BDISH positive, of which 5 of 13 cases (3 of 11 IHC0 and 2 of 2 IHC1+) harboured ≥6 copies of HER2. Overall, concordance between non-equivocal IHC and BDISH results was substantial (κ = 0.789, P < 0.001). For the 16 IHC equivocal (IHC2+) samples, using BDISH, 7 were positive, 7 negative and 2 not assessable due to technical failure, despite repeating the test with an adjusted digestion (supplementary Table S2 , available at Annals of Oncology online).
HER2 positive (EMEA definition; IHC 3+ or IHC 2+ and BDISH+) paired sample concordance HER2 status in pre-treatment biopsies and resection specimens was concordant in 145 of 156 (93%) of assessable cases (κ = 0.608, P < 0.001, substantial agreement). In discordant cases, an apparent gain of HER2 over-expression was more common than apparent loss of expression. Nine patients were HER2 negative on biopsy but positive on resection, whereas only two were HER2 positive on biopsy, but negative on resection specimen. Eight of the 11 discordant cases were in patients randomised to S. The discordance is most likely due to the (EMEA) definition of HER2 positive employed (supplementary Table S3 , available at Annals of Oncology online): Both cases that apparently lost HER2 protein expression on the resection were HER2 amplified but IHC negative (0-1+) on resection, and six of nine patients that apparently gained HER2 expression were HER2 amplified but IHC0 on biopsy (one was not assessable by BDISH, two BDISH negative). Of 46 BDISH-positive resection specimens, HER2 amplification was confirmed in 10 paired biopsies, with 5 discordant (BDISH negative) biopsies (33.3%). The overall HER2-positive rate (EMEA definition) using patients with complete IHC/BDISH results from resections (n = 327) or biopsies where no resection was provided (n = 58) was 10.9% (42 of 385).
predictive biomarker analysis: chemotherapy and HER2
For the 217 patients with established baseline HER2 status (overall treatment HR in patients with biopsy samples 0.69 (95% CI 0.42-0.81), the treatment HR in the HER2-positive population (EMEA definition; n = 15) was 0.74 (95% CI 0.14-3.77) in favour of CSC and 0.58 (95% CI 0.41-0.82) in the HER2-negative population (n = 202) (Figure 2 ). Power for testing heterogeneity was limited given the low HER2-positive rate, but there was no evidence that pre-treatment HER2 status predicted survival outcome (heterogeneity P = 0.7). As concordance between biopsy and resection was high (93%), an indirect assessment of potential predictive effect in resection specimens was also undertaken, looking for evidence of heterogeneity in the prognostic impact of HER2 status following resection across treatment groups, with again no significant effect (heterogeneity P = 0.988 using EMEA definition; P = 0.821 using US FDA definition).
prognostic impact of HER2 positivity
In patients with pre-treatment biopsies, the HER2 status (EMEA definition) HRs were similar in S and CSC patients (HR = 0.54 and 0.63, respectively) with no evidence of heterogeneity (P = 0.7). Combining treatment arms, there was a non-statistically significant association (HR = 0.58, 95% CI 0.32-1.06, log-rank P = 0.08) between HER2 positive status on pre-treatment biopsy (n = 15/217) and longer survival. However, this was not confirmed by HER2 status (EMEA definition) on resection specimens, where there was no clear prognostic effect in either treatment group alone (HER2 HRs 1.0 and 0.99 in S and CSC patients respectively, test for heterogeneity P = 0.99) or combined (HR = 0.99, 95% CI 0.62-1.59, log-rank P = 0.97). When patients who were HER2 BDISH positive but IHC negative (0-1+, n = 13) were included (FDA definition), similar results were found (Figure 3 
discussion
The MAGIC study reported a clinically and statistically significant benefit from peri-operative chemotherapy compared with S. Although tissue was not collected from all enrolled subjects, the Kaplan-Meier survival curves indicate that the patients with available specimens were representative of the comparable intention to treat biopsy and resection populations.
The rate of HER2 positive cancers (14.4% IHC3+ or BDISH+) reported here is lower than reported in advanced disease; both in the screening study for the ToGA trial (22.1%) [3] , and an international collaborative biomarker study (20.6%) [27] . Our results are more comparable to a biomarker analysis of the ACTS-GC study in early gastric cancer, where 13.6% of 829 resected gastric cancers were HER2 positive, defined by IHC3+ or IHC2+ and BDISH+ [24] . Using this definition, only 10.4% of our resections were HER2 positive, possibly reflecting ethnic variation; a large European study reported HER2 expression in <10% of gastric cancers evaluated, albeit using breast cancer HER2 scoring [12] . The differences observed suggest that HER2 over-expression/HER2 gene amplification may be more frequent in advanced than early disease. The age of the paraffin-embedded samples, however, may also have affected our results, as the reliability of immunohistochemical results for HER2 have been reported to decline with age, leading to false negatives [30] .
Our concordance between HER2 over-expression (IHC3+) and amplification was high (26 of 27 patients, 96%), consistent with previous reports [25] . However, 13 of 47 HER2-positive original articles Annals of Oncology trastuzumab. Although the assessment of HER2 was centralised and carried out using validated immunohistochemical and BDISH methodologies, scoring was carried out by a single pathologist experienced in gastrointestinal pathology. Given the inter-observer variability reported for HER2 assessment [16] , one potential limitation of this study is single-observer bias.
Our concordance between biopsies and resections was 92% for negative results and 83% for positive results. A previously published comparison of HER2 expression between biopsies and resections predates the standardisation of HER2 scoring for gastric cancer, but reported 88.5% concordance for IHC in 200 paired samples. FISH was carried out only in biopsy specimens from patients with HER2-amplified resection specimens; with 62.2% concordance (66.6% in our study). In contrast to our study, no patients received neoadjuvant therapy between the diagnostic biopsy and resection [31] . In breast cancer, changes in HER2 status between pre-treatment biopsies and resections following neoadjuvant chemotherapy have been reported in 7.6%-30% of cases, most commonly gain of expression (reviewed in [32] ). We detected a change in HER2 status in 11 patients; however, the majority (8 of 11) had concordant BDISH amplification and only discordant HER2 protein expression, likely representing heterogenous HER2 expression rather than a true change in the biology of the disease. Noteworthy, only three patients whose HER2 status differed from biopsy to resection specimen had received chemotherapy.
HER2 gene amplification [4, 5, 33] has been reported to predict for benefit from anthracycline therapy in breast cancer studies; in a meta-analysis, treatment HRs (epirubicin versus no epirubicin) were 0.73 in patients with HER2-amplified Annals of Oncology original articles tumours and 0.91 in the rest [34] . In our analysis, the estimated benefit from ECF chemotherapy in HER2-positive and -negative patients was similar (HR 0.74 and 0.58, respectively). This may be a function of the combination chemotherapy, thereby not only testing anthracycline sensitivity. However, while our power to detect an interaction was limited by our sample size of pre-treatment biopsies and the low frequency of HER2 positivity, the observed HRs did not suggest the existence of a subgroup of patients with oesophago-gastric cancer who should not be offered ECF chemotherapy. Further studies are planned to investigate whether a combination of potential anthracycline/platinum/ fluoropyrimidine biomarkers is predictive in this setting.
In contrast to breast cancer, the prognostic effect of HER2 in gastric cancer is controversial (reviewed in [35] ). This can be partially explained by the heterogeneous scoring methods before the standardised system proposed in 2008 [15] . While a recent series of resected patients with non-metastatic stage I-IV gastric cancer (n = 221) reported that HER2 amplification, but not over-expression, correlated significantly with worst survival (P = 0.023) [26] , large series of both early [24, 25] and advanced gastric cancer [27] have reported no significant prognostic impact. The latter study is consistent with observations from the ToGA study, where the original statistical calculations, based upon an assumption that HER2 conferred an adverse prognosis, were revised when a lowerthan-expected event rate was observed by the IDMC [3] . The power of our study is limited given the low frequency of HER2 positivity. Based on the pre-treatment biopsy specimens, an absolute increase in survival at 2 years of >30%, and a decrease of >2%, can be ruled out and using resection specimens, absolute differences in 2-year survival after surgery greater than a 15% increase or 21% decrease can be reliably excluded. Our results therefore, support the conclusions from recent studies that HER2 is not an independent predictor of poor prognosis in oesophago-gastric adenocarcinoma.
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